Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis by Niesporek, S et al.
Expression of lysophosphatidic acid acyltransferase beta
(LPAAT-b) in ovarian carcinoma: correlation with tumour
grading and prognosis
S Niesporek
1,5, C Denkert*,1,5, W Weichert
1,MK o ¨bel
2, A Noske
1, J Sehouli
3, JW Singer
4, M Dietel
1 and
S Hauptmann
2
1Institute of Pathology, Charite ´ University Hospital, Campus Mitte, Schumannstr. 20/21, 10117 Berlin, Germany;
2Institute of Pathology, Martin-Luther-
University Halle-Wittenberg, Magdeburger Str. 14, 06112 Halle (Saale), Germany;
3Department of Gynecology and Obstetrics, Charite ´ University
Hospital, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany;
4Cell Therapeutics Inc., 501 Elliott Avenue West, Suite 400, Seattle,
WA 98119, USA
Lysophosphatidic acid acyltransferase beta (LPAAT-b) is an enzyme involved in lipid biosynthesis whose role in tumour progression
has been of emerging interest in the last few years. We investigated the expression of LPAAT-b by reverse transcriptase–polymerase
chain reaction and immunohistochemistry in 10 ovarian cell lines as well as in a cohort of 106 ovarian tumours and normal ovaries.
Lysophosphatidic acid acyltransferase beta mRNA was found in all cell lines and ovarian tumours examined. Expression of LPAAT-b
protein was significantly increased in ovarian carcinomas compared to benign ovarian tissue (w
2 test P-value¼0.001, Kruskal–Wallis
test P-value o0.0001). Furthermore, LPAAT-b expression was positively associated with higher tumour grade (P¼0.044), higher
mitotic index (Po0.0001) and tumour stage (P¼0.032). Expression of LPAAT-b was significantly linked to reduced overall survival
time (P¼0.024) as well as to shorter progression-free survival time (P¼0.012) in patients younger than 60 years. Our study shows
that LPAAT-b is upregulated in ovarian cancer and is more prevalent in poorly differentiated tumours. In addition, LPAAT-b
expression is a predictor of a worse prognosis in patients younger than 60 years. Further studies are needed to investigate if LPAAT-b
may serve as a therapeutic target for certain subgroups of patients.
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Ovarian carcinoma, although constituting only about 5% of all
malignancies of the female genital tract, is still the gynaecological
cancer with the highest mortality (Jemal et al, 2004). This is mainly
due to the usually late detection of this neoplasm. In contrast to
breast or cervical cancer, no sufficient screening methods exist for
ovarian carcinoma and in contrast to endometrial carcinoma, it is
mostly asymptomatic in early stages. Thus, most patients are
diagnosed with stage III or IV carcinomas that have already spread
to adjacent anatomic structures in the peritoneal cavity. In these
stages, chemotherapy in addition to radical surgery is the
therapeutic option (Almadrones, 2003; Pfisterer et al, 2003).
Therefore, research on the pathogenetic basis of this neoplasm
might be of great value for the development of new molecular
therapies, which specifically target molecules that enhance
tumorigenic properties.
Lysophosphatidic acid acyltransferase beta (LPAAT-b)i sa n
enzyme that has been of growing interest in tumour research in the
last few years. It converts intracellular lysophosphatidic acid (LPA)
to phosphatidic acid (PA). Apart from its counterpart LPA that is
already well known as a stimulator of cell proliferation, migration
and survival and whose role in tumorigenesis, especially in ovarian
cancer, has been extensively examined (Mills and Moolenaar,
2003), PA has emerged as another bioactive phospholipid
important in cancer biology because of its implication in a variety
of signal transduction pathways (English, 1996). The LPAAT
family comprises several members with the most important being
LPAAT-a and LPAAT-b (Eberhardt et al, 1997; West et al, 1997;
Aguado and Campbell, 1998; Li et al, 2003). While LPAAT-a is
expressed in all human tissues and is therefore thought to have a
housekeeping function, LPAAT-b is differentially expressed, with
the highest levels in liver and heart but also in steroid hormone-
dependent tissues such as prostate, endometrium and ovary (West
et al, 1997; Leung, 2001).
In this study, we investigated the expression of LPAAT-b
by reverse transcriptase–polymerase chain reaction (RT–PCR)
and immunohistochemistry in 10 ovarian cell lines as well as
in a cohort of 106 ovarian tumours and normal ovaries. The
aim of our study was to evaluate the prognostic role of
LPAAT-b expression and its association with clinicopathological
factors.
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Cell lines
The human ovarian carcinoma cell lines OVCAR-3, SKOV-3,
MDAH-2774 and CAOV-3 have been isolated from ovarian
adenocarcinomas and were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA). OAW-42 and
A27/80 have been established from adenocarcinomas of the ovary,
and were from the European Collection of Cell Cultures (ECACC,
Salisbury, UK). EFO-27 has been established from an ovarian
adenocarcinoma and was obtained from the German Collection
of Microorganisms and Cell Cultures (DSM, Braunschweig,
Germany). The cell line ES-2 has been isolated from a poorly
differentiated ovarian clear-cell carcinoma and was from ATCC.
PA-1 has been established from an ovarian teratocarcinoma and
was from ATCC. HOSE, a normal ovarian surface epithelium cell
line, which has been immortalised by HPV, was a kind gift from
Dr SW Tsao (Universtity of Hong-Kong, Department of Anatomy)
(Tsao et al, 1995). Cell lines were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum.
Polymerase chain reaction
Tissue from ovarian carcinomas was dissected by a senior
pathologist in the operating room from surgical specimens sent
for frozen section analysis and was immediately frozen in liquid
nitrogen and stored at  801C until analysis. Tissue samples were
homogenised and total RNA was extracted with the RNeasy Kit.
Residual DNA was digested with DNase. For polymerase chain
reaction (PCR) of RNA, cDNA was made by reverse transcription.
Polymerase chain reaction was performed following the subse-
quent protocol: cycling conditions were 35 cycles of denaturation,
annealing and extension (941C for 60s, 551C for 60s, 721C for 60s).
Primers used were human LPAAT-b sense 50-CGCTCTAG
CACTGCCATGAC-30 and LPAAT-b antisense 50-CCAGCACCTG
CAATGTGACT-30 (generating a 253-bp band) and human GAPDH
sense 50-CCATGGCACCGTCAAGGCTG-30 and GAPDH antisense
50-GCCATGTGGGCCATGAGGTC-30 (generating an 828-bp band).
Study population
Immunohistochemical analysis was performed retrospectively on
tissue samples collected from 106 patients who underwent surgery
for diagnostic or therapeutic purpose at the Charite ´ University
Hospital Berlin, Germany and the RWTH Aachen, Germany
between 1989 and 2000. This study has been approved by the
ethics committee of the Charite ´ Hospital. Data on histology,
tumour size, nodal status and FIGO stage were extracted from the
pathological report at primary diagnosis. The carcinomas were
graded according to the Silverberg grading system, which takes
account of nuclear polymorphism, mitotic figure count and
architectural features (Shimizu et al, 1998). For statistical
evaluation and survival analysis, only the cases of invasive ovarian
carcinoma were included.
Follow-up data on overall survival were available for all patients.
Overall survival was defined as the time between diagnosis and
death. Data on progression-free survival were available for 51 of 76
(67%) patients. Progression-free survival was defined as the time
between diagnosis and the first clinical or pathological evidence of
local or distant disease recurrence.
Immunohistochemistry
Immunohistochemistry was performed using standard procedures.
For detection of LPAAT-b on tissue samples, we used a mouse
monoclonal antibody against human LPAAT-b, which was from
JW Singer, Cell Therapeutics, Seattle, USA (Bonham et al, 2003).
For antigen retrieval, slides were boiled for 5min in 0.01 M sodium
citrate buffer, pH 6.0, in a pressure cooker. Slides were incubated
with the primary antibody diluted 1:200 in antibody diluent
solution (Zymed, San Francisco, CA, USA) for 20min at room
temperature and then at 41C overnight. After washing slides in
TBS, a streptavidin-biotin system was applied according to a
standard protocol with standard antibody dilutions as provided by
the manufacturer (BioGenex, San Ramon, CA, USA). For colour
development, a fast red system (Sigma, Deisenhofen, Germany)
was used. After colour development was stopped, slides were
coverslipped using Aquatex (Merck, Gernsheim, Germany).
Evaluation of immunohistochemical staining
Immunohistochemical staining was evaluated by two pathologists
(CD and SN) who were blinded towards patient’s characteristics
and outcome. For semiquantitative analysis of staining, an
immunoreactivity scoring system (IRS) was applied. For this
purpose, the mean number of cells stained (0¼no cells stained,
1¼less than 10% of cells stained, 2¼11–50% of cells stained,
3¼51–80% of cells stained, 4¼more than 80% of cells stained) as
well as staining intensity (0¼negative, 1¼weak, 2¼moderate,
3¼strong) was evaluated. Subsequently, the respective score for
each case was calculated by multiplication of these two parameters.
Those cases, in which disagreement in IRS score evaluation
between both observers was evident, were discussed using a
multiheaded microscope, until agreement was achieved. For
statistical analysis, cases with an IRS of 0–6 were grouped in
one group (‘LPAAT-b-negative’) and were compared to cases with
an IRS of 7–12 (‘LPAAT-b-positive’).
Statistical analysis
Association between clinicopathological parameters and expres-
sion of LPAAT-b was assessed using either w
2 test, w
2 test for
trends, Fisher’s exact test, Kruskal–Wallis test or Mann–Whitney
test. Survival curves were established by the Kaplan–Meier
method and compared by applying a log-rank test. Generally,
P-values smaller than 0.05 were considered significant. For all
statistical procedures, SPSS v10.0 software was used.
RESULTS
Expression of LPAAT-b mRNA in ovarian carcinoma cell
lines
To investigate expression of LPAAT-b mRNA in ovarian cancer,
we studied eight ovarian adenocarcinoma cell lines as well as one
ovarian teratocarcinoma cell line by RT–PCR. In addition, an
immortalised normal ovarian surface epithelium cell line (HOSE)
was examined. All cell lines expressed LPAAT-b mRNA constitu-
tively. Lysophosphatidic acid acyltransferase beta mRNA was
increased in most cancer cell lines compared to the normal ovarian
surface epithelium cell line HOSE. Expression level of GAPDH, the
positive control, was similar in all cell lines (Figure 1A).
Expression of LPAAT-b mRNA in ovarian carcinomas
We investigated five ovarian carcinomas, one borderline tumour,
one benign ovarian teratoma and one normal ovary (Figure 1B). A
moderate expression of LPAAT-b mRNA was detected in five
cases. Three cases, one G2 and one G3 serous carcinoma, and one
clear-cell carcinoma, showed only weak expression of LPAAT-b
mRNA. Expression level of GAPDH, the positive control, was
comparable in all cases.
Correlation with tumour grading and prognosis
S Niesporek et al
1730
British Journal of Cancer (2005) 92(9), 1729–1736 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sClinical and pathological characteristics of patients with
ovarian lesions
As our results have shown that LPAAT-b mRNA was present in
most samples from ovarian carcinomas, we further studied the
LPAAT-b protein expression by immunohistochemistry in ovarian
tissue of 106 patients. The median age at surgery was 57 years
(range 28–85 years). In all, 76 (71%) patients had an invasive
ovarian carcinoma, 16 (15%) had a borderline tumour, seven (7%)
had a benign cystadenoma and seven (7%) had normal ovaries. Of
the invasive carcinomas, 39 (51%) were of the serous type, seven
(9%) mucinous, 11 (15%) endometrioid, four (5%) clear cell, three
(4%) transitional cell and 12 (16%) undifferentiated carcinomas.
Carcinomas were well differentiated (G1) in 18 (23%) cases,
moderately differentiated (G2) in 31 (41%) cases and poorly
differentiated (G3) in 27 (35%) cases. Tumour stage was pT1 in 15
(20%) cases, pT2 in 13 (17%) cases and pT3 in 48 (63%) cases.
Data on the nodal status were available for 46 (60%) patients of
whom 25 (54%) patients had no lymph node metastasis and 21
(46%) have been classified as pN1. Four (5%) patients in our study
group had known distant metastases (pM1) at the time of
diagnosis. In all, 16 (21%) patients were staged as FIGO I, 11
(15%) as FIGO II and 45 (59%) as FIGO III. The four (5%) patients
with distant metastases were classified as FIGO stage IV.
Overall survival of ovarian carcinoma patients ranged from 0.3
to 122 months with a median survival of 35 months. A total of 35
(46%) patients died during follow-up. A total of 26 of 51 (51%)
patients had clinical or pathological evidence of disease recurrence
during follow-up. In five (19%) of these 26 patients, disease
recurrence was clinically manifest as distant metastasis, while 21
patients (81%) had a local recurrence.
Expression of LPAAT-b in ovarian tissue
Immunoreactivity for LPAAT-b was detectable in a subset of
ovarian carcinomas as well as in benign ovarian tissue.
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Figure 1 Expression of LPAAT-b mRNA in eight ovarian carcinoma cell
lines, one ovarian teratocarcinoma cell line and one normal ovarian surface
epithelium cell line (A). Expression of LPAAT-b mRNA in eight cases of
ovarian tissue. Histological diagnoses: (1) endometrioid carcinoma, G2; (2)
serous carcinoma, G3; (3) benign teratoma; (4) serous carcinoma, G2; (5)
normal ovary; (6) serous carcinoma, G3; (7) serous borderline tumour; (8)
clear-cell carcinoma (B). Expression of LPAAT-b and GAPDH was
determined by RT–PCR. bp¼base pairs.
Figure 2 Immunohistochemical detection of LPAAT-b expression in a normal ovary as well as in ovarian carcinomas. Normal ovarian surface epithelium
with weak expression of LPAAT-b (A). Serous ovarian carcinoma (G1) with moderate expression of LPAAT-b (B). Transitional cell ovarian carcinoma (G3)
with strong expression of LPAAT-b (C). Serous ovarian carcinoma (G3) with strong expression of LPAAT-b (D). In all samples shown, a weak stromal
expression of LPAAT-b is evident.
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cytoplasmatic staining pattern in tumour cells (Figure 2), which
is consistent with previous demonstration of LPAAT-b localisation
to the endoplasmic reticulum (Leung, 2001). We found a positive
staining in 50 (66%) ovarian carcinomas, whereas three (19%)
borderline tumours, two (29%) benign cystadenomas and two (29%)
normal ovaries were LPAAT-b-positive (w
2 test P-value¼0.001;
Table 1). Lysophosphatidic acid acyltransferase beta immuno-
reactivity score was significantly higher in ovarian carcinomas
than in benign ovarian tissue, which comprises borderline tumours,
cystadenomas and normal ovarian surface epithelium, as deter-
mined with the Kruskal–Wallis test (Po0.0001). Median LPAAT-b
immunoreactivity score was 8 in the cases of ovarian carcinoma,
while it was 4 in the cases with borderline tumours, cystadenomas
or normal ovarian surface epithelium (Figure 3A).
In addition, in most cases (96%), weak LPAAT-b immuno-
reactivity was found in the stroma of ovarian tumours and normal
ovaries where a homogenous staining pattern was observed.
Association of LPAAT-b expression with
clinicopathological parameters
Malignant tumours are characterised by clinicopathological para-
meters such as tumour stage and tumour grade. An association of a
certain marker with these parameters could possibly point to a
tumourbiological function of the protein.
We found a significant association of LPAAT-b expression with
tumour grading (P¼0.044) comparing low-grade cases (G1 and
G2) with high-grade cases (G3) (Table 2). As the Silverberg grading
system includes nuclear polymorphism, mitotic frequency and
Table 1 Expression of LPAAT-b in normal ovaries and different types of
ovarian tumours
Tissue type All cases
LPAAT-
b-negative
LPAAT-
b-positive P-value
Invasive carcinoma 76 (100%) 26 (34%) 50 (66%)
Borderline tumour 16 (100%) 13 (81%) 3 (19%)
Cystadenoma 7 (100%) 5 (71%) 2 (29%)
Normal ovary 7 (100%) 5 (71%) 2 (29%) 0.001
a
aPearson’s w
2, two-sided.
Table 2 Association of LPAAT-b expression and various clinicopatho-
logical factors
Characteristic All cases
LPAAT-
b-negative
LPAAT-
b-positive P-value
Histological type 64 (100%) 25 (39%) 39 (61%)
Differentiated
Undifferentiated 12 (100%) 1 (8%) 11 (92%) 0.049
a
Histological grade (Silverberg)
G1–2 49 (100%) 21 (43%) 28 (57%)
G3 27 (100%) 5 (19%) 22 (81%) 0.044
a
PT
pT1 15 (100%) 9 (60%) 6 (40%)
pT2–3 61 (100%) 17 (28%) 44 (72%) 0.032
a
PN
pN0 25 (100%) 9 (36%) 16 (64%)
pN1 21 (100%) 7 (33%) 14 (67%) 1.0
a
PM
PMX 72 (100%) 24 (33%) 48 (67%)
pM1 4 (100%) 2 (50%) 2 (50%) 0.6
a
FIGO stage
I 16 (100%) 8 (50%) 8 (50%)
II 11 (100%) 2 (18%) 9 (82%)
III 45 (100%) 14 (31%) 31 (69%)
IV 4 (100%) 2 (50%) 2 (50%) 0.47
b
Residual tumour
o 2cm 26 (100%) 9 (35%) 17 (65%)
42cm 6 (100%) 1 (17%) 5 (83%) 0.64
a
Chemotherapy
Platinum-based CTX 44 (100%) 16 (36%) 28 (64%)
Other CTX 4 (100%) 1 (25%) 3 (75%)
No CTX 7 (100%) 4 (57%) 3 (43%) 0.4
c
Age at surgery (years)
o60 45 (100%) 17 (38%) 28 (62%)
460 31 (100%) 9 (29%) 22 (71%) 0.47
a
aFisher’s exact test, two-sided.
bw
2 for trends.
cPearson’s w
2, two-sided.
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Figure 3 Median immunoreactivity score for LPAAT-b staining in
normal ovaries, cystadenomas, borderline tumours and ovarian carcinomas
(P¼P-value, Kruskal–Wallis test) (A). Median number of mitoses (per 10
HPF) in tumours positive and negative for LPAAT-b (P¼P-value Mann–
Whitney test) (B). N¼number of cases; HPF¼high-power field.
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immunoreactivity with these factors. Expression of LPAAT-b
showed a significant positive correlation with mitotic figure count
(per 10 HPF), as determined by the Mann–Whitney test
(Po0.0001) (Figure 3B). No association of the expression of the
enzyme could be observed with nuclear polymorphism or
architectural features.
A significant positive association (P¼0.032) of LPAAT-b
expression with tumour stage could be established. Tumours of
the pT2 and pT3 stages were more frequently positive for LPAAT-b
than tumours of the pT1 stage (Table 2). Significant associations of
LPAAT-b expression with neither nodal status nor state of distant
metastasis could be observed. Also, no significant association with
FIGO stage was evident.
Consistent with the association of LPAAT-b expression and
tumour grade, we found that undifferentiated carcinomas had a
significantly higher LPAAT-b immunoreactivity than carcinomas
of a distinct histological type (serous, mucinous, endometrioid,
transitional cell or clear cell) (P¼0.049) (Table 2).
Stromal expression of LPAAT-b was associated with neither
epithelial expression of the protein nor with any clinicopatholo-
gical parameter.
Univariate survival analysis
The known prognostic factors in ovarian carcinoma like FIGO
stage, state of metastasis as well as tumour grade and age at
diagnosis were prognostic factors for overall survival (Table 3)
as well as for progression-free survival (Table 4) in our study
group.
Median overall survival was 41.5 months for patients with
LPAAT-b-positive carcinomas, while it was not reached at the end
of follow-up in the group of patients with LPAAT-b-negative
carcinomas (Figure 4A). Nevertheless, this difference was not
statistically significant (P¼0.17). Similarly, there was no signifi-
cant difference in progression-free survival (P¼0.11) between
both groups (not shown). However, we found that LPAAT-b
positivity was a negative prognostic parameter in patients younger
than 60 years at the time of diagnosis. As shown in Figure 4B, the
median overall survival time for patients younger than 60 years
with LPAAT-b-positive tumours was 41.5 months, while it was not
reached for patients of the same age group with LPAAT-b-negative
tumours (P¼0.024). Similarly, progression-free survival was
significantly shorter in patients younger than 60 years with
LPAAT-b-positive tumours (21.3 months vs not reached, P¼0.012;
Figure 4D). Patients with LPAAT-b-positive tumours had similar
frequences of local recurrence and distant metastasis as patients
with LPAAT-b-negative tumours (not shown). No significant
difference in progression-free or overall survival according to
LPAAT-b was determined for patients older than 60 years (not
shown). A preliminary explorative multivariate analysis for the two
age groups indicated that the number of cases was too small to
obtain reliable results. Survival analysis was not biased by
differences in therapy as LPAAT-b expression was associated with
neither residual tumour mass nor type of chemotherapy (Table 2).
DISCUSSION
In this study, we systematically determined the expression of
LPAAT-b mRNA as well as LPAAT-b protein in vivo and in vitro in
ovarian carcinomas and in benign ovarian tissue. We found that
LPAAT-b mRNA was expressed in all ovarian tissue samples and
all ovarian cell lines examined. On the protein level, LPAAT-b was
expressed in most ovarian carcinomas (66%) but only in a
minority of benign ovarian samples. Comparative analysis finally
Table 3 Univariate Kaplan–Meier survival analysis: median overall
survival time of all patients with invasive ovarian carcinoma in dependence
of clinicopathological factors and LPAAT-b expression
Characteristic
No. of
cases
Median survival
time (months)
Standard
error
Log-rank
P-value
LPAAT-b expression
Negative 26 Not reached —
Positive 50 41.5 8.4 0.17
Histological type
Differentiated 64 51.4 6.6
Undifferentiated 12 17.8 — 0.24
PT
pT1 15 Not reached —
pT2 13 61.6 21.8
pT3 48 41.2 4.6 0.12
PN
pN0 25 61.6 —
pN1 21 Not reached — 0.4
FIGO stage
I 16 Not reached —
II 11 52.5 18.4
III 45 41.5 7.0
IV 4 1.7 5.3 o0.00001
Histological grade
(Silverberg)
G1 18 Not reached —
G2 31 47.5 5.4
G3 27 34.8 5.6 0.013
Age at surgery (years)
o60 45 61.6 —
460 31 35.5 15.9 0.044
Table 4 Univariate Kaplan–Meier survival analysis: median overall and
progression-free survival time of patients with invasive ovarian carcinoma in
different age groups in dependence of LPAAT-b expression
Characteristic
No. of
cases
Median survival
time (months)
Standard
error
Log-rank
P-value
Overall survival
Age o60
LPAAT-b expression
Negative 17 Not reached —
Positve 28 41.5 6.9 0.024
Age 460
LPAAT-b expression
Negative 9 17.9 1.6
Positive 22 35.5 15.2 0.29
Progression-free survival
Age o 60
LPAAT-b expression
Negative 14 Not reached —
Positve 18 21.3 14.2 0.012
Age 460
LPAAT-b expression
Negative 7 17.6 4.8
Positive 12 29.8 7.5 0.28
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ovarian carcinomas compared to normal ovarian surface epithe-
lium, cystadenomas and borderline tumours. Consequently, our
study shows an overexpression of LPAAT-b in malignant ovarian
tissue.
Our finding that LPAAT-b expression was upregulated in
invasive ovarian carcinomas is consistent with other studies,
which reported LPAAT-b upregulation in malignant tissue:
LPAAT-b mRNA expression determined by Northern blot analysis
was low to moderate in normal ovarian, breast and prostate tissue
while it was high in the corresponding malignant tissue (Leung,
2001). Tissue expression of the protein as determined by
immunohistochemistry was elevated in malignant neoplasms of
the prostate, breast, lung, colon, cervix, brain as well as ovary
compared to normal tissue of the same type (Bonham et al, 2003).
Furthermore, cell culture experiments showed that prostate
carcinoma cell lines expressed LPAAT-b at a higher level than
normal prostate cell strains and that this correlated with an
increase with LPAAT-b activity (Bonham et al, 2001, 2003).
In our study, we found an increased LPAAT-b expression in
poorly differentiated tumours as well as an association with
tumour size and high mitotic count. This indicates that LPAAT-b
expression may be involved in the regulation of tumour cell
proliferation. This hypothesis, on the functional level, is supported
by the results of other authors who reported that transduction and
overexpression of the LPAAT-b gene in weakly transformed cancer
cells in vitro lead to the ability to proliferate in low serum
(Bonham et al, 2001, 2003). These data suggest a cause and effect
relationship between LPAAT-b function and tumour progression,
as opposed to just circumstantial evidence of increased expression
in tumours; it appears to be a selective advantage to tumours,
possibly by enhanced response to growth factors in cell signal-
ling pathways requiring PA. Phosphatidic acid, the product of
LPAAT-b, has been shown to play an important role in several
signal transduction pathways that stimulate proliferation and
prevent apoptosis. Thus, it is necessary for translocation of raf
to membranes, a step being essential for raf activation (Andresen
et al, 2002). Furthermore, PA is involved in mTOR activation
(Fang et al, 2001), which in turn plays a role in the Akt/PI3K
pathway in preventing apoptosis. There is evidence that PA can
directly activate ERK (Andresen et al, 2002). In addition,
overexpression of LPAAT-b, but not the alpha isoform, cDNA in
Xenopus oocytes enhanced both raf- and ras-mediated activation
of ERK and associated germinal vessel breakdown (Coon et al,
2003). Phosphatidic acid is also implicated in the activation of Rho
family proteins like Rac (Chuang et al, 1993), RhoA (Lee et al,
1998) and Arf (Manifava et al, 2001). These small GTPases in
regulating the actin cytoskeleton play a role in cellular migration
and invasion and, in addition, promote cell cycle progression by
regulation of cell cycle proteins like p21 and cyclin D1 (Etienne-
Manneville and Hall, 2002). Further messenger functions of PA
include EGFR internalisation (Shen et al, 2001), vesicle formation
(English, 1996; English et al, 1996) and calcium homeostasis
(English, 1996; English et al, 1996). Several of these pathways are
activated in ovarian carcinoma as was shown for EGFR, PI3K or
Akt (Berchuck et al, 1990; Wenham et al, 2002; Zhang et al, 2003).
Enhanced PA signalling in LPAAT-b-overexpressing tumours may
contribute to this deregulation and result in tumour growth and
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Figure 4 Univariate survival analysis (Kaplan–Meier) for all 76 patients with invasive carcinomas. There was no significant difference in median overall
survival in patients with tumours negative or positive for LPAAT-b (A). For patients younger than 60 years, median overall survival was significantly reduced if
they had tumours positive for LPAAT-b (B). Patients with LPAAT-b-positive tumours showed no significant difference in progression-free survival compared
to patients with LPAAT-b-negative tumours (C). Lysophosphatidic acid acyltransferase beta positivity in patients younger than 60 years was a predictor of
reduced progression-free survival (D). P¼P-value, log-rank test.
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sdedifferentiation. Phosphatidic acid-mediated activation of Rho
proteins, which have been shown to be implicated in the
progression in ovarian cancer (Horiuchi et al, 2003), could
enhance invasion, metastasis and proliferation. The hypothesis
that PA itself has an impact on ovarian carcinoma tumorigensis
is supported by the fact that PA directly stimulates proliferation
in ovarian cancer cell lines (Xu et al, 1995). Our finding of an
increased LPAAT-b expression in worse differentiated and more
advanced tumours may reflect these biological mechanisms.
Further evidence for an important role of LPAAT-b in human
cell signalling pathways came from experiments with specific
LPAAT-b inhibitors. Treatment of smooth muscle cells, in which
cell signalling pathways have been well characterised, decreased
phosphorylation of ERK, Akt and mTOR (Coon et al, 2003).
Moreover, LPAAT-b inhibition of a variety of human tumour cell
lines leads to a proliferation arrest in G2–M and subsequent
apoptosis (Bonham et al, 2003; Coon et al, 2003; Hideshima et al,
2003). Interestingly, a proapoptotic effect of the LPAAT-b
inhibitors was found in most tumour cell lines, which also
comprised ovarian cancer cell lines, but not in some normal cell
types, even when high concentrations of inhibitors were used
(Bonham et al, 2003; Coon et al, 2003). Lysophosphatidic acid
acyltransferase beta, which normally is expressed in low levels in
most normal tissues, may not be necessary for survival of these
normal cells, but the malignant cells may be more dependent on its
activity. Thus, a future scenario in cancer therapy might be to use
LPAAT-b inhibitors for patients with LPAAT-b-overexpressing
tumours to specifically suppress multiple pathways of neoplastic
cell growth.
In the present study, LPAAT-b positivity was a predictor of
unfavourable outcome with respect to overall and progression-free
survival in patients, younger than 60 years. This might indicate
that in younger patients, hormonal influences act together with
LPAAT-b expression to worsen the prognosis. In this context,
studies on the impact of oestrogen and progesterone on LPAAT-b
regulation would be of great interest. Lysophosphatidic acid
acyltransferase beta expression might be of prognostic value only
for certain subgroups of patients, as the expression of the enzyme
was no prognostic marker for overall or progression-free survival
in the whole study population. A limitation of our study was the
relatively small patient number (n¼76), which lowers the power
of a survival analysis, especially when performed for subgroups.
For this reason, we could not perform a multivariate survival
analysis for the different age groups.
Lysophosphatidic acid acyltransferase beta is an interesting new
target for chemotherapeutical intervention in patients with ovarian
carcinoma. Our study shows that LPAAT-b is upregulated in
ovarian cancer and is more prevalent in less-differentiated
tumours. In addition, LPAAT-b expression was a predictor of a
worse prognosis in patients younger than 60 years. Large-scale
prospective and retrospective studies are needed to establish
whether LPAAT-b expression could be of diagnostic value as a
prognostic parameter for certain subgroups of patients. Further-
more, the mechanism of LPAAT-b upregulation in tumours
remains to be elucidated.
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